Meri Rogava

Years Active: 2021-2024
Publications (10 Years): 4

This page only lists publications with an associated author ORCID identifier.

Publications

Trang Thi Thu Nguyen, Qiuqiang Gao, Jeong-Yeon Mun, Zhe Zhu, Chang Shu, Aaron Naim, Meri Rogava, Benjamin Izar, Mike-Andrew Westhoff, Georg Karpel-Massler, Markus D Siegelin
Suppressing PD-L1 Expression via AURKA Kinase Inhibition Enhances Natural Killer Cell-Mediated Cytotoxicity against Glioblastoma. Cells 13 (13) (2024)
Trang Thi Thu Nguyen, Qiuqiang Gao, Jeong-Yeon Mun, Zhe Zhu, Chang Shu, Aaron Naim, Meri Rogava, Benjamin Izar, Mike-Andrew Westhoff, Georg Karpel-Massler, Markus D Siegelin
Suppressing PD-L1 Expression via AURKA Kinase Inhibition Enhances Natural Killer Cell-Mediated Cytotoxicity against Glioblastoma. Cells 13 (13) (2024)
Chris J Frangieh, Johannes C Melms, Pratiksha I Thakore, Kathryn R Geiger-Schuller, Patricia Ho, Adrienne M Luoma, Brian Cleary, Livnat Jerby, Shruti Malu, Michael S Cuoco, Maryann Zhao, Casey R Ager, Meri Rogava, Lila Hovey, Asaf Rotem, Chantale Bernatchez, Kai W Wucherpfennig, Bruce E Johnson, Orit Rozenblatt-Rosen, Dirk Schadendorf, Aviv Regev, Benjamin Izar
Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion. Nature genetics 53 (3) (2021)
Janne Ruotsalainen, Dorys Lopez-Ramos, Meri Rogava, Naveen Shridhar, Nicole Glodde, Evelyn Gaffal, Michael Hölzel, Tobias Bald, Thomas Tüting
The myeloid cell type I IFN system promotes antitumor immunity over pro-tumoral inflammation in cancer T-cell therapy. Clinical & translational immunology 10 (4) (2021)

Meri Rogava.css-eqlu8i{font-size:small;padding-left:4px;}